Director’s Introduction

On January 1st, 2009, the National Institute for Health and Medical Research (Inserm) and the Paris Descartes University created the Paris-Cardiovascular research Center (PARCC) at the Georges-Pompidou European Hospital . The official grand opening occurred on September 8th, 2009, in the presence of the minister for Research and Higher Education and the minister of Health.

Eleven teams were approved by Inserm and UP5, including two emerging young AVENIR teams, for the 2009-2013 period. For the next 2014-2018 period, 14 research teams have been approved by Inserm and Paris-Descartes University, including one AVENIR team.

They are conducting projects spanning basic molecular and cellular biology to integrated physiology and pathophysiology, biomarkers, genetics and epidemiology, with the goal of furthering the understanding of major cardiovascular disease, including atherosclerosis, hypertension, heart failure and sudden cardiac death. Translational research is an integral part of the mission of the PARCC, in close connection with clinical laboratories and departments of HEGP.

This unique site merges large and complementary areas of expertise in order to stimulate the generation of new knowledge in biology and cardiovascular medicine using multiple approaches.

The 14 teams benefit an administrative platform, shared facilities, technical and high technology platforms. A major component of our efforts also centers on the training of students, postdoctoral research fellows, junior faculty, residents, and cardiology clinical fellows.

The PARCC succeeded in bringing together an important critical mass of basic and clinician scientists, who share a vision and common objectives in the field of cardiovascular diseases, in a single location equipped with laboratories, office space and core facilities, occupying a surface of 4,200 m2.

All team leaders, as well as senior researchers, are experts internationally recognized by their peers in their respective field, which contributed to the reputation of the PARCC as a national and international leader in cardiovascular research. To conduct high quality and challenging research, scientists need an appropriate environment and re– sources to achieve their potential. In response to the unique scientific and infrastructural requirements, the PARCC has developed and set up technology platforms with cutting-edge methodologies.
We have all the tools at our disposal to simultaneously conduct basic, pre-clinical and translational research : in vitro and in vivo experimental models ; small animal housing facilities ; cell culture, cell imaging, histology ; integrative biology ; flow cytometry platform ; imaging platform ; biomarkers platform ; biostatistics ; bioinformatics ; biobanks ; cohorts; data management.

This enabled the PARCC to act as a catalyst to optimize the major translational research potential of the groups in the rapidly moving areas of cardiovascular sciences and medicine. The need to understand cardiovascular disease pro- cesses at a more refined and mechanistic level, ultimately leading to intervention, requires interdisciplinary efforts that incorporate these diverse approaches. The PARCC connects investigators from a wide spectrum of cardiovascular research that includes cellular and molecular investigation, physio(patho)logical experimentation in whole animals, investigator-initiated clinical research, population studies, and translational research that brings discoveries from the bench to the bedside.

We have strategically fostered an environment that intellectually and geographically focuses in a coordinated fashion diverse state-of-the-art talent in vascular biology and atherosclerosis (Chantal Boulanger, Eric Camerer, Hafid Ait-Oufela), hypertension ( Xavier Jeunemaitre, Maria-Christina Zennaro), kidney disease (Pierre-Louis Tharaux), angiogenesis (Jean-Sébastien Silvestre, Eric Tartour, Anne Eichmann, Judith Favier), pharmacology (Pierre Boutuyrie), molecular imaging (Bertrand Tavitian), immunology (Ziad Mallat, Eric Tartour), genetics (Nabila Bouatia-naji, Xavier Jeunemaitre, Anne-Paule Gimenez-Roqueplo), epidemiology (Xavier Jouven, Jean-Pulippe Empana, Alexandre Loupy), cell therapy (Philippe Menasché) and cardiology (Jean-Sébatsien Hulot) in order to tackle unmet medical needs in cardiovascular diseases.

255 permanent positions and non-permanent staff

› 20 permanent researchers, › 58 university-hospital affiliated faculty, › 8 hospital staff, › 28 post doctoral fellows, › 35 PhD students, › 43 permanent technical assistants, › 18 non-permanent technical assistants, › 45 undergraduates. › Fellows from 22 different countries


2005 The first stone of the building is laid at HEGP. 2006 The decision is made by Inserm, Paris Descartes University, Fondation Alain Carpentier and Assistance Publique-Hôpitaux de Paris (the owner of the building) to dedicate the new research building mainly, even though non-exclusively, to cardiovascular research. An international call for recruiting the director of the HEGP Research Center is launched. 2007 Nomination of Alain Tedgui, Inserm Director of research, as director of the HEGP Research Center. Selection of the first 8 research teams of the center, following evaluation of the projects by an international Review Committee. 2008 First site visit of the Evaluation of Research and Higher Education (AERES) committee. 2009 Creation by Inserm and the Paris Descartes University of the Paris- Cardiovascular Research Center (PARCC). Official grand opening in the presence of the minister for Research and Higher Education and the minister of Health. 2013 Second visit of AERES committee. 2014 Re-creation by Inserm and the Paris Descartes University of the Paris- Cardiovascular Research Center (PARCC). 2019 Re-creation by Inserm and the Université de Paris of the Paris- Cardiovascular Research Center (PARCC) with Chantal Boulanger as new Director.